Literature DB >> 25565388

Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease and its association with depressive symptoms and suicidality.

A A M Hubers1, R C van der Mast, A M Pereira, R A C Roos, L J Veen, C M Cobbaert, E van Duijn, E J Giltay.   

Abstract

Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis has been reported in Huntington's disease (HD). In non-HD populations, alterations in HPA axis activity have been associated with depression and suicidality. The present study aims to compare HPA axis activity between HD mutation carriers and controls, and examine its association with depressive symptoms and suicidality. To this end, salivary cortisol concentrations at seven time points, as well as depressive symptoms and suicidality, were assessed in 49 pre-motor, 102 motor symptomatic mutation carriers and 55 controls, at baseline and follow-up combined. Differences in parameters of HPA axis activity between these three groups, and their associations with depressive symptoms and suicidality in HD mutation carriers, were analysed using multilevel regression analyses. There were no differences in parameters of HPA axis activity between mutation carriers and controls, whereas pre-motor symptomatic mutation carriers had a significantly higher area under the curve to the increase (AUCi ) compared to motor symptomatic mutation carriers. In the entire HD cohort, HPA axis activity was not associated with depressive symptoms or suicidality. After stratifying mutation carriers into pre-motor, early and advanced disease stages, β values differed between these groups. Remarkably, a higher AUCi was significantly associated with depressive symptoms in pre-motor and early disease stage mutation carriers, with a reverse nonsignificant association in advanced disease stage mutation carriers. The lower AUCi in motor symptomatic mutation carriers and the varying associations with depressive symptoms and suicidality in pre-motor, early and advanced disease stages could possibly be explained by exhaustion of the HPA axis after prolonged stress-induced HPA axis hyperactivity and deserves further longitudinal study.
© 2015 British Society for Neuroendocrinology.

Entities:  

Keywords:  cohort study; depression; glucocorticoids; neurodegenerative diseases; suicide

Mesh:

Substances:

Year:  2015        PMID: 25565388     DOI: 10.1111/jne.12255

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  8 in total

Review 1.  A Glimpse of Molecular Biomarkers in Huntington's Disease.

Authors:  Silvia Martí-Martínez; Luis M Valor
Journal:  Int J Mol Sci       Date:  2022-05-12       Impact factor: 6.208

2.  Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.

Authors:  Brett D Dufour; Jodi L McBride
Journal:  Exp Neurol       Date:  2016-07-02       Impact factor: 5.330

Review 3.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

4.  Antioxidant Treatment Induces Hyperactivation of the HPA Axis by Upregulating ACTH Receptor in the Adrenal and Downregulating Glucocorticoid Receptors in the Pituitary.

Authors:  Jessika P Prevatto; Rafael C Torres; Bruno L Diaz; Patrícia M R E Silva; Marco A Martins; Vinicius F Carvalho
Journal:  Oxid Med Cell Longev       Date:  2017-05-09       Impact factor: 6.543

5.  Investigating the relationships between hypothalamic volume and measures of circadian rhythm and habitual sleep in premanifest Huntington's disease.

Authors:  Danielle M Bartlett; Juan F Domínguez D; Alvaro Reyes; Pauline Zaenker; Kirk W Feindel; Robert U Newton; Anthony J Hannan; James A Slater; Peter R Eastwood; Alpar S Lazar; Mel Ziman; Travis Cruickshank
Journal:  Neurobiol Sleep Circadian Rhythms       Date:  2018-07-03

6.  The Role of Hypothalamic Pathology for Non-Motor Features of Huntington's Disease.

Authors:  Rachel Y Cheong; Sanaz Gabery; Åsa Petersén
Journal:  J Huntingtons Dis       Date:  2019

7.  Hair and salivary cortisol and their relationship with lifestyle, mood and cognitive outcomes in premanifest Huntington's disease.

Authors:  Travis Cruickshank; Tenielle Porter; Simon M Laws; Mel Ziman; Danielle M Bartlett
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

Review 8.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.